Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Deep clinical evidence library with data collected from more than 1,400 subjects demonstrating dramatic improvement over today's standard of care
IONIQ's ProLung Test designated “Breakthrough Device” by US FDA for its life-enhancing potential
More than 25 premier cancer institutions across 3 continents have participated in our clinical trials
Collaborating with medical and scientific experts
Robust, growing intellectual portfolio of 22 issued and filed patents plus expert know-how
Salt Lake City, UT, February 2, 2023 – We’re delighted to unveil this visual overview of the modernization of early-stage cancer detection. IONIQ measures the body’s immune response to the presence of cancer in its earliest, most-treatable stages. And we’re doing it with no needles,
Salt Lake City, UT, January 5, 2023 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) today announced it is presenting in person at Biotech Showcase™, the investor conference for innovators. Mr. Jared Bauer, CEO, will present IONIQ Sciences at the Biotech Showcase on January
Salt Lake City, UT, December 19, 2022 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is honored to be recognized as the “Clinical Diagnostics Solution of the Year 2022” by BioTech Breakthrough Awards (link). The IONIQ team is humbled by this award and recognition of our mission
